Myasthenia gravis (MG) is an autoimmune disease causing severe muscle weakness, with an estimated prevalence of 14 to 20 per 100,000 people in the USA, and 1 to 9 per 100,000 in Europe. Many cases of MG go undetected, due to the difficulty in diagnosing the condition, but state-of-the-art disease biomarkers and targeted assays are now helping to increase the likelihood of MG patients being diagnosed early and treated appropriately.
In this webinar, Jan Damoiseaux discusses how these biomarkers and the correct use of assays can help clinicians to diagnose patients sooner, monitor therapeutic efficacy and support better treatment outcomes.The webinar discusses diagnosis of both seropositive and the more severe seronegative forms of MG, beginning with the detection and clinical relevance of acetylcholine receptor autoantibodies (ARAbs) using radioreceptor assays (RRA). The focus then switches to seronegative MG, and looks at how IBL International’s MuSK-Ab ELISA is proving invaluable for the diagnosis and monitoring of this disease, helping to improve diagnostic confidence and aid clinical management of these patients.
